MetaCap

Medicus Pharma (MDCX) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XTL Biopharmaceuticals is the larger company by market cap ($3.4 million vs $3.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MDCX+608.49%XTLB-30.81%
+2244%+1046%-151%
Oct 7, 20261 yearNov 20, 2026
MDCX+1132.36%XTLB-30.81%
+3602%+1699%-204%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MDCX versus XTLB key metrics
MetricMDCXXTLB
Share price$1.14$1.37
Market cap$3.16M$3.37M
1-day change-2.16%-5.84%
YTD return-25.82%—
1-year return-46.71%—
EPS (TTM)$-76.65$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$451.00K
Net income (latest FY)$-47.28M$-1.03M
Gross margin—0.67%
Operating margin—-481.60%
Net margin—-227.72%
52-week high$114.00$5.64
52-week low$1.06$1.37
Distance from 52-week high-99.00%-75.71%
Analyst consensusnone—
Avg. price target upside+296.48%—
Average volume116.55K6.58K
Shares outstanding2.79M2.46M
Employees164
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Medicus Pharma

MDCX stock →

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About XTL Biopharmaceuticals

XTLB stock →

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

MDCX vs XTLB FAQ

Which is bigger, Medicus Pharma or XTL Biopharmaceuticals?

XTL Biopharmaceuticals (XTLB) is larger, with a market capitalization of $3.37M compared with $3.16M for Medicus Pharma (MDCX).

Are Medicus Pharma and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons